Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140179 | 0.91 | POLB (0.57) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL1140167 | 0.90 | MEN1 (0.52) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL1140045 | 0.90 | MAPK11 (0.48) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL1139653 | 0.90 | MAPK11 (0.47) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL5789210 | 0.88 | MAPK11 (0.49) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL5785750 | 0.88 | SIRT6 (0.47) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL1140681 | 0.88 | MAPK11 (0.49) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL1140051 | 0.87 | MAPK11 (0.54) | MAPTALDH1A1MAPK11MAPK14MAPK13 | |
| SCHEMBL5785922 | 0.87 | MAPT (0.48) | MAPTPOLBALDH1A1MAPK11MAPK14 | |
| SCHEMBL5788418 | 0.87 | SIRT6 (0.55) | MAPTPOLBALDH1A1MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | MAPT 3467/4885POLB 3208/4885ALDH1A1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.